Their mechanisms of action include modulation of the gut microbiota, enhancement of intestinal barrier integrity, reduction of systemic inflammation, and improvement of lipid and glucose metabolism [1, 1315]
This study showed that GLP-1 receptor agonist use was associated with markedly diminished risks of cirrhosis (aHR: 0.72, 95%CI: 0.66-0.79) and HCC (aHR: 0.65, 95%CI: 0.56-0.76) compared to non-use throughout a mean observation period of 4.8 years, with benefits observed across different baseline liver disease stages [57]
Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease
Read the full article here: I am grateful to my supervisor, Nicklas Hjgaard-hessellund Rasmussen, for his invaluable guidance throughout this work, and the work was carried out at Steno Diabetes Center Nordjylland (SDCN)
When comparisons were made, all relevant treatment groups were included